ArticleInternational journal of transgender health2026
Short-term effects of testosterone on quality of life and sexual function among hormone naïve Thai transmasculine individuals.
Article in International journal of transgender health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Issues Associated with Gender-Affirming Hormone Therapy in Transgender Individuals: A Systematic Review Relevant to Community Pharmacy Practice.Pharmacy (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Testosterone therapy is a standard intervention for improving both physical and mental health in transmasculine individuals. The aim of this study is to identify the effects of testosterone on the quality of life and sexual function among hormone-naïve transmasculine individuals in Thailand. Methods: This prospective study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand from September 2022 to February 2024. Transmasculine individuals who met the inclusion criteria were invited to complete two questionnaires: the World Health Organization Quality of Life BREF THAI (WHO-QOL-BREF-THAI) and the female sexual function index (FSFI). Testosterone enanthate, 250 milligrams, was administered intramuscularly every 4 wk. Both questionnaires were reevaluated at 12 wk after initiation of testosterone therapy. Results: A total of 55 hormone naïve transmasculine individuals were recruited. After a 12-wk period of testosterone therapy, the WHO-QOL-BREF-THAI mean total score was significantly higher compared to baseline (94.3 versus 101.4 out of 130, Conclusion: Hormone naïve-transmasculine individuals demonstrated significantly higher overall quality of life as early as 12 wk after testosterone therapy. Among transmasculine individuals who were sexually active, total FSFI, sexual desire, and orgasm scores were also significantly better compared to baseline. The longer-term effects of testosterone therapy on quality of life and sexual function among TM need to be elucidated in further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.